Quality Of Life – A Rarely Acknowledged Key Category Within The Amnog Process in Germany von Eheberg, D, Shlaen, R, Batscheider, A, Gohlke, A

Volltext

PCV117 Clinical and Patient-Reported Outcomes of Triple Combination of Olmesartan Medoxomil (OM), Amlodipine Besylate (AML) and Hydrochlorothiazide (HCT) in Hypertensive Patients von Ehlken, B, Claus, V, Shlaen, R, Oberdiek, A.M.S

Volltext

PSS5 Visual Field Evolution in Glaucoma Patients Presenting With Different Disease Stages: Results From an Observational Study von Gerlier, L, Shlaen, R, Wolfram, C, Lamotte, M, Verboven, Y

Volltext

PSS19 Glaucoma Management Cost as A Function of Disease Stage and Treatment Changes von Gerlier, L, Shlaen, R, Lorenz, K, Lamotte, M, Verboven, Y, Pfeiffer, N

Volltext

PHP231 - Quality Of Life – A Rarely Acknowledged Key Category Within The Amnog Process in Germany von Eheberg, D., Shlaen, R., Batscheider, A., Gohlke, A.

Volltext

PSS24 QUALITY OF LIFE IN OCULAR HYPERTENSION AND PRIMARY OPEN ANGLE GLAUCOMA von Wolfram, C, Lorenz, K, Shlaen, R, Verboven, Y, Pfeiffer, N

Volltext

PCN67 MANAGEMENT OF MALIGNANT ASCITES IN GERMANY—TREATMENT PATTERNS, RESOURCE CONSUMPTION, AND COSTS von Ehlken, B, Berger, K, Shlaen, R, Gonschior, AK, Lordick, F

Volltext

PCN47 CHANGE OF ANTIFUNGAL TREATMENT PATTERNS AND ASSOCIATED COSTS IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) AFTER CHEMOTHERAPY IN A GERMAN HOSPITAL FROM 2004 TO 2006 von Boehme, A, Atta, J, Mousset, S, Steffen, B, Serve, H, Hoelzer, D, Shlaen, R, Ehlken, B, Bug, G

Volltext

HTA85 Possible Impact of Orphan Threshold Reduction to 20 Million Euro in the Framework of Early Benefit Assessment and Reimbursement Price in Germany von Batscheider, A, Shlaen, E, Rich, A, Meier, C, Weiß, K, Kovacevic, S, Greiner, RA

Volltext

POSA190 Socio-Economic Influences on County-Level Differences in COVID-19 Incidence During the Second Wave in Germany von Gossmann, JA, Meier, C, Greiner, RA, Otto, J, Shlaen, E, Batscheider, A

Volltext

POSC253 Analysis of Result of Early Benefit Assessment and Reimbursement Price After Free-Pricing Period in Germany von Batscheider, A, Shlaen, E, Rich, A, Strimitzer, K, Greiner, RA

Volltext

PIN78 County-level differences in COVID-19 cases and fatalities in Germany von Batscheider, A., Gossmann, J.A., Greiner, R.A., Shlaen, E., Antoni, B., Böckmann, D., Mittal, R., Böhm, D.

Volltext

EPH80 Survival and Best Recorded Response (BRR) in Patients With Advanced Merkel Cell Carcinoma (MCC): Analysis of a Prospective German MCC Registry Study (MCC TRIM) of the German... von Mahmoudpour, S.H., Backer, J.C., Schadendorf, D., Leiter, U., Meier, F., Herbst, R., Grabbe, S., Mohr, P., Sachse, M.M., Pföhler, C., Gerbhardt, C., Ziller, F., Zimmer, L., Boutmy, E., Hoff, S., Verpillat, P., Milano, A.F., Shlaen, M., Fu, C., Ugurel, S.

Volltext

1145P Clinical characteristics and survival of patients with advanced Merkel cell carcinoma (MCC) treated with avelumab: Analysis of a prospective German MCC registry (MCC TRIM) von Becker, J.C., Mahmoudpour, S., Schadendorf, D., Leiter-Stoppke, U., Meier, F., Herbst, R., Sachse, M., Grabbe, S., Gebhardt, C., Ziller, F., Pfoehler, C., Mohr, P., Zimmer, L., Boutmy, E., Hoff, S., Verpillat, P., Fernandez Milano, A., Shlaen, M., Fu, C., Ugurel-Becker, S.

Volltext

The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care — an observational analysis on non-small-cell lung cancer patients von Ihbe-Heffinger, Angela, Paessens, B., Berger, K., Shlaen, M., Bernard, R., von Schilling, C., Peschel, C.

Volltext

Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients von Paessens, B.J., von Schilling, C., Berger, K., Shlaen, M., Müller-Thomas, C., Bernard, R., Peschel, C., Ihbe-Heffinger, A.

Volltext

Management of Febrile Neutropenia – a German Prospective Hospital Cost Analysis in Lymphoproliferative Disorders, Non-Small Cell Lung Cancer, and Primary Breast Cancer von Ihbe-Heffinger, Angela, Paessens, Bernadette J., von Schilling, Christoph, Shlaen, Margarita, Gottschalk, Nina, Berger, Karin, Bernard, Rudolf, Kiechle, Marion, Peschel, Christian, Jacobs, Volker R.

Volltext

Cost analysis of febrile neutropenia (FN) management in three tumour types in Germany von Ihbe-Heffinger, A., Paessens, B. J., von Schilling, C., Ehlken, B., Shlaen, M., Berger, K., Görtz, A., Bernard, R., Peschel, C., Jacobs, V. R.

Volltext

Resource Use and Costs Associated with Routine Management of Febrile Neutropenia in German Hospitals von Ihbe-Heffinger, Angela, Paessens, Bernadette, Jacobs, Volker R., Ehlken, Birgit, Shlaen, Margarita, Berger, Karin, Bernard, Rudolf, Peschel, Christian, Goertz, Anita, von Schilling, Christoph

Volltext

PCN42 COST ANALYSIS OF SEPSIS MANAGEMENT AFTER MYELOSUPPRESSIV CHEMOTHERAPY IN NSCLC AND LYMPHPOMA PATIENTS: A GERMAN HOSPITAL PERSPECTIVE von Paessens, B, Berger, K, Ihbe-Hefflnger, A, Mueller-Thomas, C, Shlaen, M, Von Schilling, C, Bernard, R, Peschel, C, Schramm, W

Volltext